Abstract
Biologic disease-modifying anti-rheumatic drugs (DMARDs) represent a potent treatment option for patients with immune-mediated inflammatory diseases.1 Yet, infections make up the largest proportion of serious adverse events associated with biological DMARD therapy.2 Throughout the COVID-19 pandemic, patients receiving immunosuppressive treatment were shown to be at higher risk of severe disease outcomes.3 Vaccination could prevent these outcomes, but the efficacy of COVID-19 vaccines in these patients is incompletely understood.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
